| Page 44 | Cafepharma

You are here

Primary tabs

Microbiome Company Receives Funding from Canadian Govt to Develop New Microbiome Testing Platform for Managing Chronic Disease

Post date: September 12, 2018 - 9:30am

Ph III Trial Shows Improved Outcomes with Tremfya after Failure With Humira

Post date: September 12, 2018 - 9:14am

OncoResponse Books $40 Million in Series B Financing

Post date: September 11, 2018 - 9:08am

OPKO Responds to Nasdaq Halt of Trading of Common Shares

Post date: September 11, 2018 - 8:55am

Under Fire for Risk/Efficacy Profile – Nuplazid Shows Potential for Treating Dementia-Related Psychosis

Post date: September 10, 2018 - 9:53am

Scilex Raises $140 Million to Support Commercialization of Non-Opioid Topical Pain Medication System

Post date: September 10, 2018 - 9:13am

National Comprehensive Cancer Network Releases New Guidelines for Cabometyx for Advanced Renal Cell Carcinoma

Post date: September 7, 2018 - 9:44am

Synthetic Biologics Announces Trial with Cedars-Sinai to Study SYN-010 for the Treatment of IBS-C

Post date: September 6, 2018 - 12:16pm

Synlogic Reports Positive Interim Ph I/IIa Data for Microbiome Based Treatment for Phenylketonuria

Post date: September 6, 2018 - 12:03pm

Allogene Therapeutics Banks $120 Million in Private Financing

Post date: September 6, 2018 - 9:37am

Pages